article
Pioneering cellular therapies for age-related diseases
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
List view / Grid view
Therapeutics
news
Reprogramming gut cells to treat short bowel syndrome
A preclinical study conducted by researchers at Weill Cornell Medicine have demonstrated a new gene-editing strategy to treat short bowel syndrome (SBS), a life-threatening condition in which patients lack a functional small intestine.
news
Promising psoriasis treatment reduces symptoms without steroids
A team of scientists from the University of Birmingham has discovered a powerful new treatment for psoriasis. The treatment uses a tripeptide that has shown steroid-level effectiveness in reducing symptoms, offering fresh hope for the long-term management of this chronic skin condition.
news
Key PKD findings could accelerate development of new treatments
Rutgers researchers have discovered new insights into how polycystic kidney disease (PKD) progresses, which could lead to more targeted treatments. This breakthrough may help improve therapies for PKD patients in the future.
article
Advanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
news
Bacteria-boosted nanoparticles offer a triple threat against cancer
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.
article
Spirulina’s role in shaping the future of preventative biologics
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we…
article
Early evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
news
Study aims to stop Alzheimer’s with stem cell infusions
Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer's disease before symptoms emerge, an approach that could revolutionise treatment strategies, offering new hope for at-risk individuals.
news
Identifying a new target for metabolic liver disease treatment
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
news
Stem cell study uncovers shared genes for hearing and vision repair
New research, led by USC Stem Cell scientists, has identified key genetic barriers to sensory cell regeneration in the ear and eye, paving the way for future drug therapies to restore hearing and vision.
article
The rising impact of biomarkers in early clinical development
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
article
Advancements in hit identification for membrane protein drug discovery
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
news
PSPC1 knockout slows AML in preclinical models
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
article
Next-gen biotech: rBIO’s approach to affordable insulin solutions
rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.
